Engineering the Next Generation of CAR T Therapy:
Dual target strategy; in vivo innovation
Pipeline
Tempest is a clinical-stage CAR-T company building the future of in vivo CAR-T therapy with broad potential benefit for patients with autoimmune diseases or cancer
News
September 11,
2026
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
September 8,
2026
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
August 13,
2026
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update